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Abstract
Background: The objective of the present study was to evaluate the effectiveness of postoperative radiotherapy
after breast conserving surgery (BCS) in DCIS in a large patient population treated in clinical practice.
Methods: Data were provided by the population-based Munich Cancer Registry. Between 1998 and 2014, 1048
female patients with diagnosis of DCIS and treated at two Breast Care Centres were included in this observational
study. The effectiveness of postoperative radiotherapy and variables predicting the use of radiotherapy were
retrospectively analysed.
Results: After adjusting for age, tumour characteristics and therapies, Cox regression analysis for local recurrence-free
survival identified RT as an independent predictor for improved local control (HR: 0.579; 95%CI: 0.384–0.872, p = 0.008).
Ten-year cumulative incidence of in-breast recurrences was 20.0% following BCS, compared to 13.6% in patients
receiving postoperative radiotherapy (p = 0.012). As an estimate for disease-specific survival, 10-year relative survival was
105.4% for patients receiving postoperative radiotherapy and 101.6% without radiotherapy. On multivariate analysis,
postoperative radiotherapy was not associated with improved overall survival (HR 0.526; 95%CI: 0.263–1.052, p = 0.069).
Over time, a significant increase of RT was registered: while 1998 only 42.9% of patients received postoperative
radiotherapy, the proportion rose to 91.2% in 2014. Women aged < 50 years (OR: 2.559, 95%CI: 1.416–4.625, p < 0.
001) or with negative hormone receptor status (OR: 2.625, 95%CI: 1.458–4.728, p = 0.001) or receiving endocrine
therapy (OR: 1.762, 95%CI: 1.060–2.927, p = 0.029) were more likely to receive postoperative radiotherapy after BCS.
Conclusions: In conclusion, this study provides insights regarding the adoption and treatment pattern of postoperative
RT following BCS for DCIS in a large cohort reflecting “real-life” clinical practice in this setting. Postoperative RT was found
to be associated with a reduced risk of ipsilateral recurrence and no survival benefit compared to observation alone.
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Background
The optimal management of ductal carcinoma in situ
(DCIS) of the breast is still controversial and to date, incon-
sistent and conflicting results have been reported across
prospective and observational studies [1]. As known from
several randomised trials and a large EBCTCG meta-
analysis [2–6] postoperative radiotherapy (RT) after breast
conserving surgery is a very effective adjuvant local treat-
ment modality. Radiotherapy approximately halves the risk
of local recurrences [6] as compared to surgical resection
alone, with similar effects in reducing ipsilateral in situ and
invasive recurrences [4]. This effect was observed in all
subgroups of patients and could not be translated into a
survival benefit in randomised studies [6]. Therefore, over
the past years a risk-benefit debate for or against postopera-
tive radiotherapy has attracted wide public attention [1, 7].
DCIS of the breast represents a very heterogeneous dis-
ease, making a risk-group stratification challenging. Con-
siderable efforts have been spent in the implementation of
risk-adapted treatment concepts. One major objective was
to identify a subset of “low-risk” patients with excellent
prognosis, where a treatment de-escalation with omission
of radiotherapy can be safely attempted, as recurrence rates
are very low [8, 9]. On the other hand, considerations
about a possible undertreatment of “high-risk” patients
have led to treatment escalation strategies using boost
irradiation to the tumour bed to further increase local
control rates [10, 11].
The above-mentioned uncertainties result in a vast
heterogeneity of criteria influencing treatment decision-
making in real-world settings. Clinicians have to choose
from a range of available risk stratification tools [12–14]
and treatment options in order to select a suitable treat-
ment strategy for each individual patient. Furthermore,
shared decision-making in daily clinical practice is strongly
influenced by a number of confounding factors, such as
clinician and patient preferences and trade-offs concerning
toxicity risks or comorbidities [15–17]. The aim of the
present study was to evaluate the effectiveness of postoper-
ative radiotherapy in DCIS in a large patient population,
outside of clinical trials. Moreover, the study aimed to
identify possible factors related to the use of postoperative
radiotherapy in daily clinical practice.
Methods
Data sources
Data were retrieved from the Munich Cancer Registry
(MCR) [18]. The catchment area of the population-
based clinical cancer registry to date encompasses 4.81
million inhabitants in southern Germany. Over the past
decades it has been stepwise enlarged from 2.3 million
inhabitants in 1998 to 3.84 million in 2002, and
nowadays includes all regions of Upper Bavaria. The
MCR systematically retrieves cancer notifications from
73 MCR-affiliated hospitals or other notifying institu-
tions. Patient’s demographics, cancer diagnosis, disease
and treatment characteristics and follow-up are reported
following official documentation guidelines for cancer
registries [19, 20]. Follow-up was conducted following
the national German “S3-guideline” for breast cancer
[21], with regularly clinical and mammographic follow-
ups. All follow-up data were provided as cancer notifica-
tions from MCR-affiliated hospitals or other notifying
institutions on a regular basis and collected prospect-
ively at the MCR. Moreover, all pathology laboratories
within the catchment area of the MCR are required to
submit their pathology reports to the cancer registry.
Thus, the total number of pathologically diagnosed re-
currences within the catchment area was systematically
obtained. Survival information is maintained systematic-
ally from death certificates of 23 health offices within
the catchment area of the MCR.
Study population
For the present study, patients treated at the Red Cross
Breast Centre and the LMU Breast Centre in Munich
(Germany) between 1998 and 2014 were analysed. Of all
breast malignancy records, male patients (n = 63), cases
with histology of lymphoma (n = 10), sarcoma (n = 58) or
invasive carcinoma (n = 13,064), or with unknown date
of initial diagnosis (e.g. tumors from death certificate
information only [DCO]) (n = 58), as well as cases with a
previous diagnosis of cancer or simultaneous cancer
diagnoses (n = 3200) were excluded from the analysis. Of
the remaining cases, patients who underwent mastec-
tomy (n = 296), did not undergo any surgery (n = 8), or
cases where surgery information or pathologic tumour
stage was incomplete or missing (n = 58) were not
included in the present study. The final study cohort
encompassed 1048 patients, who underwent breast
conserving surgery for ductal carcinoma in situ over a
17-year period at two Breast Centres. Follow-up was
completed on October 5th 2016.
Statistical analyses and endpoints
Statistical analyses were conducted using IBM SPSS Sta-
tistics 24.0 and R environment for statistical computing
and visualization (version. 3.4.0). Patient and treatment
characteristics were analysed using descriptive statistics
and analysed using the Chi Square test. The percentages
of the presented subcategories were related to the sum
of available data of each variable and did not consider
missing values. Primary endpoints were the impact of
postoperative radiotherapy on local control and overall
survival (OS). In-breast recurrence (IBR) was defined as
invasive or in-situ recurrence in the ipsilateral breast. To
account for competing risks, cumulative incidence ana-
lysis (CI) was used to calculate time to IBR and
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differences were assessed by Gray’s Test for Equality of
Cumulative Incidence Functions. OS was estimated
using the Kaplan-Meier method and compared using the
log-rank test. Relative survival was calculated by the
ratio of the overall survival rate to the expected survival
rate and 95% confidence intervals (95%-CI) were used
for assessing significance. To account for competing
risks, Cox proportional hazards models were used to
identify independent prognostic factors related to local
recurrence free survival (LRFS) and OS. Furthermore,
factors influencing the use of postoperative radiotherapy
in DCIS were determined by using a multivariate logistic
regression analysis. The significance level in all analyses
was set at 5%.
Results
Patient and treatment characteristics of 1048 patients di-
agnosed with ductal carcinoma in situ between 1998 and
2014 are summarized in Table 1. Median follow-up was
88.0 months; 69.0 months for the radiotherapy group
and 123.0 months for patients receiving BCS alone.
Overall, 388 patients underwent breast conserving
surgery alone, while 660 patients were treated with
additional postoperative radiotherapy of the ipsilateral
breast. Age at diagnosis was significantly different
between the groups (p < 0.001). Patients in the BCS
group were significantly older, with a median age of
58.8 years (range: 30–90), as compared to a median age
of 57.3 years (range: 28–89) in patients undergoing BCS
and postoperative radiotherapy. While tumour side was
balanced between the two cohorts, there were a number
of significant differences between patients undergoing
BCS and patients receiving additional postoperative
radiotherapy. High tumour grade (G3) was present in
29.3% of the surgery only group. The proportion was
significantly higher in patients undergoing radiotherapy,
presenting with 49.9% grade 3 tumours (p < 0.01).
Similarly, negative hormone receptor status was more
frequent in the radiotherapy group, as compared to
patients not receiving radiotherapy (17.3% vs 10.4%, p =
0.012). Nodal involvement (pN1) was present in 2 irradi-
ated patients (0.3%), while there was no case in the BCS
group. Furthermore, patients in the radiotherapy cohort
underwent surgical axillary intervention more frequently
(sentinel lymph node biopsy or axillary dissection) as
compared to the BCS cohort (18.2% vs. 10.6%, p =
0.016). Regarding other treatment modalities, irradiated
patients received endocrine therapy in 18%. In contrast,
in patients receiving no radiotherapy, adjuvant endocrine
therapy was administered in 8.5% (p < 0.001). A signifi-
cant increase in the use of postoperative radiotherapy
was documented over time (see Fig. 1). In 1998, only
42.9% of patients received postoperative radiotherapy
following BCS, whereas the proportion increased to
Table 1 Cohort characteristics of the different treatment groups.
BCS: breast conserving surgery
BCS BCS + Radiotherapy
388 patients 660 patients
n (%)a n (%)a p-value
Age at diagnosis (years)
< 50 96 (24.7) 150 (22.7) < 0.001
50–69 224 (57.8) 448 (67.9)
≥ 70 68 (17.5) 62 (9.4)
median age (years) 58.8 57.3
Tumor side
Left 217 (56.5) 354 (53.6) 0.368
Right 167 (43.5) 306 (46.4)
unknown [4] [1.0]
Tumour stage
pTis 388 (100) 660 (100)
Tumour size
< 25 mm 26 (74.3) 41 (66.1) 0.404
≥ 25 mm 9 (25.7) 21 (33.9)
unknown [353] [90.9] [598] [90.6]
Nodal status
pN0 45 (11.6) 139 (21.1) < 0.001
pN1 0 (0.0) 2 (0.3)
pNx/unknown 343 (88.4) 519 (78.6)
Grade
G1 44 (29.9) 63 (13.3) < 0.001
G2 60 (40.8) 175 (36.8)
G3 43 (29.3) 237 (49.9)
unknown [241] [62.1] [185] [28.0]
Multifocality
no 365 (94.1) 633 (95.9) 0.178
yes 23 (5.9) 27 (4.1)
Resection margins
R0 235 (97.1) 554 (96.5) 0.666
R1–2 7 (2.9) 20 (3.5)
Rx/unknown [146] [37.6] [86] [13.0]
Hormone Receptor
positive 215 (89.6) 492 (82.7) 0.012
negative 25 (10.4) 103 (17.3)
unknown [148] [38.1] [65] [9.8]
Endocrine therapy
no 355 (91.5) 542 (82.1) < 0.001
yes 33 (8.5) 118 (17.9)
aPercentages of the presented subcategories are related to the sum of each
item with available data; missing values are not taken into account
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91.2% by 2014. The standard radiotherapy regimen at the
Department of Radiation Oncology of LMU University was
whole-breast irradiation (50.4 Gy in 28 fractions or 50 Gy
in 25 fractions) followed by a boost of 10–16 Gy to the
tumour bed in high-risk cases with close resection margins.
During follow-up, 93 patients developed a DCIS recur-
rence and 50 patients an invasive ipsilateral recurrence.
Median time to in-situ recurrence was 45 months (range:
5–149 months) and 69 months (range: 11–152 months)
for invasive IBR. In-breast recurrence rates were signifi-
cantly influenced by postoperative radiotherapy (Table 2).
Cumulative incidence (CI) analysis showed a 10-year CI of
IBR of 20.0% following BCS, compared to 13.6% in pa-
tients receiving postoperative radiotherapy (p = 0.012,
Fig. 2a). Overall, 10-year CI of DCIS IBR was 11.2% as
compared to 6.5% for invasive recurrences. Other vari-
ables, including tumour age, size and grade, multifocality,
resection status, hormone receptor status or the use of ad-
juvant endocrine therapy did not significantly influence
outcome on univariate analysis. In multivariate Cox
regression analysis accounting for confounding factors,
postoperative radiotherapy remained independently
associated with improved local recurrence free survival
(hazard ratio [HR]: 0.579; 95%CI: 0.384–0.872, p = 0.008).
Results are summarized in Table 3.
Patients receiving postoperative radiotherapy had a
higher 10-year OS (96.7%) compared to patients under-
going breast conserving surgery alone (90.0%) (p =
0.001). In order to estimate disease-specific survival
rates, relative survival was calculated. Ten-year relative
survival was 105.4% for patients receiving postoperative
radiotherapy and 101.6% without radiotherapy (Fig. 2b).
After adjusting for risk factors in the Cox proportional
hazards regression model, postoperative radiotherapy
was not associated with improved overall survival (HR
0.526; 95%CI: 0.263–1.052, p = 0.069). Other risk factors
than age did not correlate with improved OS (Table 3).
Factors associated with the use of postoperative
radiotherapy
A multivariate logistic regression analysis was performed to
identify factors associated with the administration of
postoperative radiotherapy in our collective (Table 4).
Variables associated with the use of postoperative radiother-
apy included young age at diagnosis, negative hormone
receptor status, and administration of adjuvant endocrine
therapy. Women aged < 50 years were more likely to
receive postoperative radiotherapy after BCS (OR 2.559,
95%CI 1.416–4.625, p < 0.001). Similarly, women presenting
with negative hormone receptor status had higher odds for
being irradiated following BCS (OR 2. 625, 95%CI 1.
458–4.728, p = 0.001). Furthermore, postoperative radio-
therapy was more likely in patients receiving adjuvant
endocrine therapy (OR 1. 762, 95%CI 1.060–2.927, p =
0.029).
Discussion
The present observational study analysed data from a
large patient population treated at two major German
breast centers outside of clinical trials. Women treated
Fig. 1 The use of postoperative radiotherapy over time
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with postoperative radiotherapy following BCS for DCIS
of the breast were found to have a significantly lower
rate of ipsilateral recurrences as compared to BCS alone
(20.0% vs 13.6%). This difference is consistent with other
observational and randomised studies [3, 22, 23]. For
example, the population-based SEER data analysis of
1103 women diagnosed with DCIS by Warren et al. [22],
found a risk of developing an ipsilateral recurrence of
11% for patients who received postoperative radiother-
apy versus 15% for women undergoing BCS alone, at a
mean follow-up of 91 months. Accordingly, the NSABP
B-17 trial [3] documented a 15-year cumulative
incidence of ipsilateral recurrences of 19% for the lump-
ectomy group compared to 8% for the additional postop-
erative radiotherapy group. Similar results were seen in
the EORTC 10853 trial [23], where radiotherapy reduced
the incidence of invasive local recurrences after DCIS
from 13% to 8% (p < 0.01) after 10 years follow-up. The
large EBCTCG meta-analysis [6] confirmed, that postop-
erative RT after breast conserving surgery approximately
halves the risk of local recurrences as compared to
surgical resection alone, with similar effects in reducing
ipsilateral in situ and invasive recurrences.
It is well known, that postoperative RT reduces the risk
of local recurrences for all subgroups, independent of age.
Nevertheless, the EORTC trial [23] found that local recur-
rence rates were significantly influenced by age at diagnosis,
and young age < 40 years was identified as an independent
high-risk factor for ipsilateral recurrences on multivariate
analysis. Furthermore, the beneficial effect of RT on local
control seems to be modified by age, resulting in a larger
risk reduction for elderly patients. In the Swedish SweDCIS
trial [2], women younger than 52 years had a smaller abso-
lute risk reduction as compared to older age groups. The
EBCTCG meta-analysis [6] confirmed that the proportional
Table 2 Cumulative incidence of in-breast recurrences (IBR) and
Kaplan-Meier estimates of overall survival (OS)
IBR OS
5 y (%) 10 y (%) p 5 y (%) 10 y (%) p
Age at diagnosis (years)
< 50 12.6 17.6 0.251 100.0 98.5 < 0.001
50–69 9.7 16.4 98.2 95.1
≥ 70 7.0 13.8 88.1 74.6
Tumour localisation
Left 9.4 14.8 0.134 97.0 93.0 0.830
Right 11.0 18.3 97.6 93.8
Tumour size
< 25 mm 12.6 17.5 0.274 96.7 94.9 0.225
≥ 25 mm 6.7 6.7 88.9 84.2
Grade
G1 12.0 22.4 0.212 93.3 93.3 0.444
G2 5.3 12.4 96.6 95.3
G3 11.7 15.9 99.4 90.7
Multifocality
no 10.0 16.2 0.592 97.3 93.4 0.972
yes 11.1 19.4 97.6 93.1
Resection margins
R0 9.3 15.6 0.526 97.6 93.1 0.953
R1–2 14.8 20.2 96.2 96.2
Hormone receptor status
positive 8.6 16.2 0.719 97.2 94.3 0.501
negative 13.0 15.6 97.6 90.1
Radiotherapy
no 13.2 20.0 0.012 95.1 90.0 0.001
yes 8.0 13.6 99.1 96.7
Endocrine therapy
no 10.9 17.4 0.111 97.2 93.6 0.319
yes 5.5 10.7 97.6 92.3
Fig. 2 Cumulative incidence of in-breast recurrences (a) and relative
survival (b)
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reduction in the rate of ipsilateral breast recurrence
achieved with radiotherapy was greater in older than in
younger women. Lately, additional efforts have been under-
taken to further increase local control rates for this “high-
risk” group of young patients, for example by the addition
of a boost to the tumour bed. A retrospective analysis of
Moran et al. [10] showed that an additional RT boost had a
significant benefit in decreasing in-breast recurrences in
4131 patients (HR 0.68, 95%CI: 0.50–0.91, p = 0.01). Data
from current randomised trials are eagerly awaited [24, 25].
It remains unclear, how many patients received a boost in
the present study population, as detailed information on
radiation dose was not available from cancer registry data.
The effect of radiotherapy on survival in ductal carcin-
oma in situ of the breast remains unclear. As DCIS is a
non-invasive precursor lesion, overall survival after DCIS
is very good, resulting in breast cancer specific survival
rates of over 95% after 20 years [2]. So far, no statistically
significant effect on breast cancer-specific survival has
been observed in randomised trials [6]. It has to be men-
tioned, that most randomised trials were not powered to
find a difference in breast-cancer specific survival or
overall survival [13]. Furthermore, early detection and
treatment of in situ recurrences (salvage mastectomy)
might reduce the difference in outcome and result in
comparable survival rates. On the other hand, it is well
known, that patients with a subsequent invasive local
recurrence have a significantly increased mortality risk
after such events. In the EORTC trial [23], mortality risk
increased by a factor of five and breast cancer-specific
mortality by a factor of 17 following an invasive local
Table 3 Multivariate Cox regression analysis for loco-regional recurrence-free survival (LRFS) and overall survival (OS) for DCIS
LRFS OS
Variable HR 95% CI p HR 95% CI p
Age at diagnosis 0.089 < 0.001
< 50 years 1 1
50–69 y 1.014 0.625–1.645 4.809 0.639–36.165
≥ 70 y 0.423 0.180–0.994 34.505 4.594–259.164
Radiotherapy 0.008 0.069




no 1.125 0.412–3.077 0.822 0.194–3.482
Resection margins 0.424 0.948
R0 1 1
R1–2 1.449 0.583–3.602 1.049 0.246–4.474
Endocrine Therapy 0.097 0.274
yes 1 1
no 1.710 0.906–3.226 0.621 0.265–1.458
Table 4 Adjusted Odd Ratios (OR) and 95% Confidence
Intervals (CI) from the multiple logistic regression analysis for
postoperative radiotherapy compared to omission of
radiotherapy
Variable OR 95% CI p
Age at diagnosis < 0.001
< 50 years 2.559 1.416–4.625
50–69 y 2.761 1.701–4.481
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recurrence. In contrast to randomised evidence, Sagara
et al. [13] recently reported the outcome of a large
population-based study of 32,144 DCIS patients. In this
study, the use of radiotherapy in high-risk patients (high
nuclear grade, young age, large tumor size) was associ-
ated with a significant survival benefit when compared
to observation alone (HR 0.73, 95%CI; 0.62–0.88, p =
0.003). After adjusting for risk factors in the Cox propor-
tional hazards regression model in the present study,
postoperative radiotherapy was not associated with im-
proved overall survival (HR 0.526; 95%CI: 0.263–1.052,
p = 0.069). In order to estimate disease-specific survival
rates, relative survival was calculated by adjusting the
observed overall survival to the expected survival rates
from the general population in Germany. Each individ-
ual of the study population was matched by age, sex and
calendar year with the expected mortality of national life
tables. Estimates of 10-year relative survival were 105%
for patients receiving postoperative radiotherapy. A rela-
tive survival higher than 100% indicates that non-cancer
life expectancy was more favorable among patients
within this study as compared to the general population.
This “healthy user effect” is a known source of sampling
bias in observational studies of early stage breast or
prostate cancer [26–28]. Patients diagnosed with DCIS
through a screening examination, generally tend to be
healthier and have a longer life expectancy than the gen-
eral population as they are concerned for their health,
seek preventive services and might also partake in other
healthy behaviors as well as follow medical advice.
The results have to be interpreted with caution, as any
retrospective approach has inherent limitations: As known
from other observational studies [15, 29], outcome in
clinical effectiveness research is influenced by a number of
unmeasured confounding factors and associations between
treatments, and outcomes can result from confounding
and have no causal correlation [30, 31]. We tried to control
for all known confounders available in the registry, which
may have influenced the clinical treatment decision-
making process. Nonetheless, it is not possible to fully con-
trol for host-related factors including comorbidities, per-
formance status, or clinician- and patient-related
preferences. Therefore, an unavoidable limitation is the in-
herent potential for selection bias due to disease severity
[32], considering that the severity of the disease (e.g. pres-
ence of high-risk factors) is a potential confounder influen-
cing the indication for postoperative radiotherapy in DCIS.
In fact, the postoperative radiotherapy group of the present
study included significantly more patients presenting with
high-risk features like high tumour grade or negative hor-
mone receptor status. Efforts have been undertaken to ac-
count for these clinicopathological risk-score features in
multivariate analysis. However, a proper risk-group stratifi-
cation to categorize baseline risks for local recurrence was
not possible, since molecular subtypes and histopatho-
logical parameters were not available for all patients from
the database. A strength of our study might be, that - in
contrast to the highly selected and homogeneous study
populations of randomised trials - this observational study
reflects a heterogeneous cohort of patients treated in real-
world clinical practice.
In the present analysis, a significant increase over time
(1998–2014) regarding the use of postoperative radiother-
apy was observed. This change in the use of RT probably
results from the publication of four randomised trials con-
ducted in the early nineties [2–4, 23]. While mastectomy
was the treatment of choice until the 1980s, these trials
seem to have influenced treatment decisions in real-world
clinical scenarios. Our analysis strongly confirms the
change of treatment patterns: while in 1998 only 42.9% of
patients received postoperative radiotherapy following
BCS, this percentage has risen to 91.2% in 2014. Factors
associated with the use of postoperative radiotherapy on
multivariate logistic regression analysis were typical high--
risk features, as young age at diagnosis or negative hor-
mone receptor status. Similar results were reported by
Subhedar et al. [33], who retrospectively analysed 2996
cases of DCIS undergoing BCS from 1978 to 2010 at a
single institution. Despite a significant increase of RT use
over time (p < 0.0001), recurrence rates have fallen over
time, even in patients undergoing BCS alone. The authors
postulate that advances in digital mammography and im-
provements in pathological assessment might contribute
to the reduction in recurrence rates [33].
Unfortunately, there are no widely accepted guidelines
helping to stratify patients in clinical practice. Further pro-
spective studies will be needed to clarify the debated role of
RT in DCIS and assist clinicians to tailor risk-adapted RT
strategies for their DCIS patients. In clinical practice, thor-
ough counselling on the risk-benefit profile using prognos-
tic scores [12, 13] or even multigene expression assays [34,
35] should be recommended for informed decision-making.
The main challenge remains the selection of low-risk pa-
tients, in whom RT provides negligible absolute benefit and
can be safely omitted, as well as to identify women at high
risk, in order to be able to discuss advantages and disadvan-
tages of a RT boost on an individual basis. Furthermore,
patient compliance with follow-up care and the need for
regular mammography surveillance play an important role
in clinical decision making outside of randomised trials.
Conclusion
In conclusion, the present study provides insights regard-
ing the adoption of postoperative RT following BCS for
DCIS in a large cohort, reflecting “real-life” clinical prac-
tice in this setting. Postoperative RT was found to be asso-
ciated with a reduced risk of ipsilateral recurrence and no
survival benefit compared to observation alone.
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